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Over the years, not only have the T-cell mediated immune mechanisms of aplastic anemia 
(AA) involved in AA development started to become better understood, but there is now also 
a better understanding of the roles played by somatic mutations, cytogenetic abnormalities 
and defective telomerase functions and other genetically-related factors.  
Somatic gene mutations suggestive of clonal hematopoiesis are detected in approximately one 
third of patients with AA. Recent studies have suggested that some of these may predict a 
better response to immunosuppressive therapy, whereas others indicate poorer outcomes with 
higher risks of clonal evolution to myelodysplastic syndrome or acute myeloid leukemia, and 
that therefore better results may be obtained based on allogeneic stem cell transplantation. 
Furthermore, recent advances in molecular techniques may be useful in differentiating 
aplastic anemia from hypocellular myelodysplastic syndrome and other clonal 
hematopoiesises of indeterminate potential. All of these are summarized in this review which 
includes further insights into treatment personalization based on the molecular pathogenesis 
of AA. 







Aplastic anemia (AA) is a rare form of bone marrow failure caused by autoimmune 
destruction of hematopoietic progenitor stem cells with a clinical picture dominated by 
pancytopenia [1, 2]. 
For many years, it was thought to be based solely on the response of T-cell mediated 
immune mechanisms to toxic agents, including cytotoxic drugs, some medications, 
irradiation, toxins or infections such as viruses [3, 4]. In the majority of cases, some genetic 
abnormalities are also relevant. In all cases, an extensive differential diagnostic work-up 
should be performed (Table I) to exclude other pancytopenia causes (Table II) and thus to 
establish the diagnosis of AA. The appropriate decisions and choices of therapy, along with 
an assessment of risk stratification, are based on the Camitta classification of AA (Table III) 
[5–7]. 
The incidence of AA is, on average, 2 cases per million in Europe. The incidence is 
roughly three times higher in Asia, which may indicate some genetic or environmental factors 
[8–11]. Several hypotheses have been proposed to explain why the incidence of AA is higher 
in Asia than in Europe and North America, but the most probable seems to be host genetics 
such as HLA types and nucleotide polymorphisms in some cytokine genes [12]. There is no 
difference in the incidence of AA between men and women, but as most cases are observed 
before the age of 40, a genetic predisposition to AA has been suggested. Although clonal 
evolution of AA to paroxysmal nocturnal hemoglobinuria (PNH), hypocellular 
myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) is often observed [13], 
co-existing somatic mutations may predispose to this process. 
Irrespective of the identification of the cause of pancytopenia in the course of AA, the 
responses to immunosuppressive treatment confirm the thesis of autoimmune injury to 
hematopoietic stem cells and stem cell progenitors [14–16]. The primary role of T-cell 
cytotoxic lymphocytes along with the additional effect of interferon gamma and TNF on the 
inhibition of hematopoietic stem cell (HSCs) production together with an increasing FAS 
receptor expression (the first sign of apoptosis) all contribute to immune-mediated destruction 
of HSCs [17–22]. The Human Leukocyte Antigen (HLA) genes play key roles in mediating 
the immune response, especially HLA class II alleles. A Chinese study identified HLA-
DRB1, DQB1 and DPB1 alleles predisposing to AA development [23]. The dysfunction of T 
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regulatory cells is increased NK cells and autoantibodies, which are also involved in HSC 
immune destruction in AA [24–28]. 
 
 
Table I. Proposed diagnostic procedures for aplastic anemia (AA) 
Category Tests 
Peripheral blood testing CBC, differential, reticulocyte count 
Flow cytometry for PNH 




Rheumatoid disease screening Antinuclear antibodies 
Rheumatoid factor 
Liver function tests ALT, AST, Bilirubin serum levels 
Viral infection testing HBV, HCV, EBV, CMV, HHV-6, HIV, Parvovirus B19 
Visual imaging CT, PET-CT, MRI, US for searching solid tumors and 
lymphoproliferative neoplasms 
CBC — complete blood count; PNH — paroxysmal nocturnal hemoglobinuria; ALT — 
alanine transaminase; AST — aspartate transaminase; HBV — hepatitis B virus; HCV — 
hepatitis C virus; EBV — Epstein-Barr virus; CMV — cytomegalovirus; HHV-6 — human 
herpesvirus 6; HIV — human immunodeficiency virus; CT — computed tomography; PET-
CT — positron emission tomography-computed tomography; MRI — magnetic resonance 
imaging; US — ultrasonography 
 
 
Table II. Differential diagnosis of aplastic anemia (AA) 





















HBV — hepatitis B virus; HCV — hepatitis C virus, EBV — Epstein-Barr virus; CMV — 
cytomegalovirus; HHV-6 — human herpesvirus 6; HIV — human immunodeficiency virus; 
MDS — myelodysplastic syndrome; AML — acute myeloid leukemia; ALL — acute 
lymphoblastic leukemia; NHL — non-Hodgkin’s lymphoma; HCL — hairy cell leukemia; 
PNH — paroxysmal nocturnal hemoglobinuria; HLH — hemophagocytic lymphohistiocytosis 
 
 




Bone marrow cellularity <25% (or 25–50% with <30% residual 
hematopoietic cells), plus at least two of the following peripheral 
blood findings: 
Neutrophils <0.5 ×109 
Platelets <20 ×109/L 




As SAA, but neutrophils less than 0.2 ×109/L 
Non-severe aplastic 
anemia (NSAA) 
Criteria for SAA or VSAA not fulfilled and decreased bone marrow 
cellularity, plus at least two of the following peripheral blood 
findings: 
Neutrophils <1.5 ×109 




Inherited bone marrow failure syndromes 
 
Several genetic disorders including Schwachman-Diamond syndrome (which leads to a 
reduction in hematopoietic stem cells’ ability to repair DNA because of genetic lesions), 
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congenital amegakaryocytic thrombocytopenia (MPL gene), Diamond Blackfan anemia 
(SBDF gene), Fanconi anemia, some GATA2 spectrum disorders, congenital keratosis, 
SRP72, and congenital pure red cell aplasia have all been identified as familiar cases of AA 
[29–34]. Careful history-taking and physical examinations may be helpful in the identification 
of germ-like genetic bone marrow failure disorders associated with AA and included in 
differential diagnostics in children, adolescents and young adults (Table IV) [6, 35]. Next-
generation sequencing technologies have facilitated the discovery of mutations that cause 
pancytopenia and lead to aplastic anemia. All of them carry a high risk of MDS/AML, and 
some of them are associated with an especially high risk of a range of solid tumors. Thus a 
tailored stem cell transplantation regimen, such as reduced intensity conditioning, may be the 
optimal treatment. This is especially true for Fanconi anemia, dyskeratosis congenita, 
Diamond Blackfan anemia, and Shwachman-Diamond syndrome, not only because of the 
high risk of clonal evolution, but also due to the high risk of morbidity and mortality [36–38]. 
 
Table IV. Selected anomalies in physical examination indicative of inherited AA 
Anomaly Disease or mutation 
Short stature 
FA, DKC, DBA, SDS, 
SAMD9 
Microcephaly FA, DKC 
Café-au-lait skin lesions FA 
Abnormal skin pigmentation, dystrophic nail and oral 
leucoplakia 
DC 
Skeletal anomalies SDS 
Erythema nodosum, warts and molluscum GATA2 
Absent radii TARS 
Abnormal thumbs FA, DBA 
Hypertelorism, epicanthal folds DBA 
Cerebellar ataxia SAMD9L 
FA — Fanconi anemia; DBA — Diamond Blackfan anemia; SDS — Shwachman-Diamond 
syndrome; DC — dyskeratosis congenita; CAMT — congenital amegakaryocytic 
thrombocytopenia; TARS — thrombocytopenia-absentradii syndrome 
 
Somatic mutations in AA 
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Recurrent mutations and variants have been detected in up to 50% of patients with AA using 
targeted next generation sequencing hematopoiesis [39–42]. Although some of these 
mutations are limited to AA, such as PIGA [43] and BCOR/BCORL1 mutations, others are 
frequently found in myeloid malignancies, including ASXL1 and DNMT3A. Moreover, 
DNMT3A-mutated and ASXL1-mutated clones tend to increase in size over time, whereas 
BCOR- and BCORL1-mutated and PIGA-mutated clones decrease or remain stable [44]. 
 
Impact of somatic mutations on outcomes 
 
Several reports have evaluated the clinical significance of somatic mutations in AA. Firstly, it 
has been shown that the response to immunosuppressive therapy is better in patients with 
PIGA, BCOR and BCORL1 mutations [45]. In the study by Hosokawa et al., the presence of 
increased glycosylphosphatidylinositol-anchored protein-deficient cells correlated with a 
positive response to immunosuppressive therapy and prognosis, and thus was found helpful in 
choosing the optimal treatment for trisomy +8 patients with AA or low-risk MDS [45]. 
Although the natural history of AA patients with PNH clones has been studied, no impact on 
progression to symptomatic PNH or transformation to AML/MDS has been observed [46]. 
Furthermore, higher rates of overall and progression-free survival have been found in these 
subgroups of mutations [44]. However, other somatic mutations such as DNMT3A and 
ASXL1 are associated with worse outcomes. Recently, a study into mutation status and the 
differences between severe and non-severe AA by Patel et al. [47] detected at least one 
mutation in 19% of patients with AA at the time of diagnosis, independent of the severity of 
the AA. However, patients with severe AA had a higher mutation rate compared to moderate 
AA (56% vs. 19%), which corresponds to the unstable hematopoietic clones and higher risk 
of clonal evolution [47]. 
Finally, the effect of somatic mutations on a higher risk of progression to MDS/AML 
was revealed by Kulasekararaj et al. [42]. Furthermore, other specific mutations are likely 
predictors of secondary MDS [48]. The effect of the therapy applied also influences the 
mutational status, and BCOR/BCORL1 mutations may expand during the course of IST [48]. 
Negoro et al. demonstrated that, in serial samples of AA without evolution to MDS, clones 
with GATA2, PHF6, RUNX1, SMC3, TET2 and BCORL1 mutations decreased in size during 
the course of AA, whereas ASXL1, CALR, CUX1, ETV6, EZH2, G3BP1, RIT1, U2AF1, and 
ZRSR2 expanded. In contrast, DNMT3A, BCOR, and CEBPA clones showed individually 
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variable behavior with regard to clonal dynamics [48]. Lastly, Negoro et al. also demonstrated 
the clinical impact of MDS-driver mutations found in AA at presentation, which transformed 
to MDS and had a shorter median progression-free survival and overall survival compared to 
cases without such somatic alterations [48]. Other researchers have postulated that clonal 





Telomere shortening is found in up to 35% of patients with AA [49, 50]. It is known that this 
can result in chromosomal instability and may lead to evolution to MDS/AML [51]. To resist 
the attrition, germ-like cells utilize telomerase reverse transcriptase (TERT), telomerase RNA 
component (TERC) telomerase genes, and the stabilizing protein dyskerin (DKC1) to 
assemble the telomerase complex and maintain telomere length [52]. It has been found that 
several mutations in TERT, TERC-DKC1 (stabilizing protein dyskerin) and RTEL1 (regulator 
of telomere elongation helicase 1) are associated with telomere shortening in AA patients [53, 
54]. 
Shortened telomere length at diagnosis in patients with AA has been shown to 
correlate with poorer outcomes [55–57], particularly due to an inadequate response to 
immunosuppressive therapy. Moreover, some mutations like TERT or TERC mutations [54, 
58] are associated with transformation to MDS/AML [51, 55, 59, 60]. Sex hormones or other 
pharmacological agents have been shown to be effective in up-regulating telomere length and 
reducing the risk of clonal evolution to AML [61]. A frequency of up to 38% of clonal 




The most common cytogenetic abnormality is monosomy 7 (-7), occurring in up to 13% of 
AA cases. Overall, this is associated with a poorer prognosis and a high risk of progression to 
MDS or AML [63, 64]. Evaluation of the karyotypes in patients with MDS secondary to AA 
revealed the presence of chromosomes 6, 7 and 8 abnormalities [64] which suggests that these 
cytogenetic abnormalities, at the initial diagnosis or developed later in patients with AA, can 
promote progression to MDS/AML. Some cytogenetic abnormalities such as trisomy 8 or 
del(13q) are associated with a favorable response to immunosuppressive therapy [65–67]. 
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Although they are commonly found in other myeloid malignancies, they are related to a low 
risk of transformation to MDS or AML [57, 63, 68]. There are many cytogenetic 
abnormalities whose clinical impact on outcomes remains to be established [69]. 
 
Circulating exosomal microRNAs 
 
MicroRNAs (miRNAs) can regulate T cell differentiation and plasticity by targeting their 
corresponding message RNAs (mRNAs), which play important roles in many autoimmune 
diseases and also AA [70–73].  
Among several specific miRNAs which regulate RNA silencing and post-
transcriptional regulation of gene expression to have been studied in AA and MDS, Guidice et 
al. identified 25 exosomal microRNAs uniquely or frequently present in AA and/or MDS 
[74]. One of these, mir-126-5p, with its higher expression at diagnosis in patients with AA, 
was associated with a shorter progression-free survival and a poorer response to therapy. In 
another study by Hosokawa, two miRNAs were identified: miR-150-5p which regulated the 
induction of T-cell differentiation, and miR-146b-5p which was involved in innate immune 
response. Both of these increased in AA patients, whereas miR-1 was decreased in AA [75]. 
Moreover, the elevated expression of miR-150-5p was significantly reduced after successful 
immunosuppressive therapy but did not change in non-responders, indicating the clinical 
utility of miR-150-5p for disease monitoring [75]. 
 
Management of patients with aplastic anemia 
 
Prior to initiating treatment for AA, other causes of pancytopenia should be excluded, 
particularly inherited bone marrow failure syndrome (IBMFS), hypoplastic MDS and some 
others transient causes of pancytopenia including drugs or infections. As AA may be 
associated with PNH, detection of the PNH clone is more indicative for AA than any other 
cause of pancytopenia and bone marrow failure. Although allo-HSCT is considered to be the 
only curative procedure for patients with SAA, it is recommended that younger patients, 
particularly children, undergo careful evaluation of concomitant illnesses and performance 
status to determine unfit or frail patients before intensive therapies, including allo-HSCT or 
IST (ATG or CsA), due to treatment-related mortality and morbidity [76–78]. Figure 1 shows 
a practical therapeutic algorithm in SAA [EBMT algorithm for SAA in 2019, modified] [5]. 
In cases of the detection of clonal hematopoiesis, especially monosomy 7 (-7) or other 
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abnormalities related to high-risk MDS or insufficient response to IST in patients with SAA 
below the age of 60, if these patients are assessed as eligible for transplant but have no 
identical sibling donor, an alternative donor should be sought. 
 
 




Clonal hematopoiesis and supportive therapy 
 
All patients with AA require ongoing supportive care to alleviate symptoms and reduce the 
adverse effects related to pancytopenia. Most studies have reported that infections were the 
predominant cause of death; therefore recommendations for infection prevention are included 
in several guidelines, independent of the intensity of AA treatment, both for transplant- or 





Hematopoietic growth factor, granulocyte colony stimulating factor (G-CSF) stimulates 
granulocyte progenitors as well as stem cells for proliferation and differentiation. A 
randomized prospective trial on patients with newly diagnosed severe AA (n =192), receiving 
antithymocyte globulin and cyclosporine, with and without G-CSF, did not demonstrate any 
impact of G-CSF on the outcome of severe AA, independent of cytogenetic abnormalities. 
Overall survival and progression-free survival was comparable in both groups, as well as the 
risk of clonal abnormalities and myeloid neoplasm development [82]. Moreover, the results of 
a metanalysis of four studies confirm that the usage of G-CSF in IST is not associated with a 
higher occurrence of clonal evolution into malignant neoplasm and PNH in SAA patients 
[83]. On the other hand, a rapid granulocyte recovery in patients treated with IST with G-CSF 
addiction may identify early non-responders, and perhaps indicate the need for urgent 




Eltrombopag (EPAG), an oral thrombopoietin (TPO) receptor agonist used in immune 
thrombocytopenia treatment, is a new therapeutic option in transplant-ineligible SAA patients. 
The role of TPO in hematopoiesis is not limited only to thrombopoiesis: a TPO receptor c-
Mpl is present on hematopoietic stem and progenitor cells (HSPCs), and its lack in murine 
models leads to HSPC deficiency [86]. EPAG is efficient at SAA refractory to IST and in 
some patients it restores trilineage hematopoiesis with a sustained response even after 
discontinuation of the treatment [87–89]. Nevertheless, a risk of clonal evolution during this 
treatment remains an area of concern. Two prospective studies of EPAG usage in treatment 
naïve and second in refractory/relapsed SAA have not shown a higher risk of clonal evolution 
or myeloid neoplasm development compared to historical data [87, 88]. On the other hand, in 
phase 1 / 2 EPAG in R/R SAA (18%) have developed new cytogenetic abnormalities, most of 
these (87%) within six months of beginning treatment. However, some were unstable and 
disappeared after EPAG withdrawal. Chromosome 7 abnormalities were observed in 8% 
(7/83) of patients, and four of them had persistent aberration in control cytogenetic testing one 
month after drug discontinuation. Nevertheless, none of them progressed to MDS/AML [88]. 
The impact of EPAG on the overall risk of cytogenetic progression, clonal evolution, 
and/or clinical progression to MDS/AML in patients with SAA requires further investigation. 
Due to an insufficient response to IST, patients who are platelet transfusion-dependent may 
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receive EPAG as secondary SAA therapy, but its high costs limit the widespread 
application of this treatment option in many countries [79, 90]. 
 
Survival after hematopoietic stem cell transplantation (HSCT) 
 
A recent study demonstrated that in some situations, despite the identification of certain 
genetic abnormalities of germline monoallelic deleterious variants in the Fanconi anemia gene 
in patients with idiopathic AA (21 variants in 730 patients), the abnormalities do not influence 
the outcome of hematopoietic cell transplantation [91].  
Generally, although allogeneic HSCT has shown an improvement in survival rates, 
particularly for HLA-matched unrelated donor transplants, haploidentical transplantation has 
been proposed as the effective treatment for severe aplastic anemia and it is increasingly 
being used [15]. The optimal choice of haploidentical donor has also been the subject of 
research [92]. Furthermore, a recent meta-analysis of 5,336 patients comparing front-line 
treatments for AA showed significantly longer survival among AA patients undergoing first-
line allo-HSCT compared to IST. On the other hand, one of the most important complications 
after allo-HSCT is graft-versus-host disease, and this needs to be carefully balanced against 
the concerns of IST [93].  
It has to be emphasized that the choice of initial treatment for patients with newly 
diagnosed AA still requires a comprehensive evaluation of donor availability, patient age, 




There are difficulties in differentiating between AA and MDS due to the high prevalence of 
clonal hematopoiesis in AA with genetic abnormalities overlapping with MDS. Furthermore, 
a better understanding of the pathogenesis of AA with respect to somatic mutations, 
cytogenetic abnormalities and defective telomerase functions, and their impacts on the 
response to IST, along with a balancing of the risk of clonal progression to MDS/AML, may 
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